| Biomarker ID | 389 |
| PMID | 18948370 |
| Year | 2008 |
| Biomarker | Serum PSA + DRE + Methylation Status of RASSF1 |
| Biomarker Basis | Methylation Based |
| Biomolecule | mRNA |
| Source | Expressed Prostatic Secretion |
| Subjects | Humans |
| Regulation | Hypermethylated in Prostate Cancer |
| Odds Ratio/Hazard Ratio/Relative Risk | OR =0.961 (95% CI: 0.405–1.784) |
| Effect on Pathways | Pathways Include:-Bladder cancer,Non-small cell lung cancer,p53 activity regulation,Pathways in cancer |
| Experiment | (Benign Samples + Gleason sums < 7) Vs ≥ 7 |
| Type of Biomarker | Diagnostic |
| Cohort | Of the 74 specimen cohort, only the 63 that yielded >300 ng total nucleic acid were used for DNA methylation analysis. Patients with Benign + Gleason sum <7 (n = 52) and Gleason sum >7 (n = 11) were chosen as the cohort. |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.696 (95% CI: 0.539–0.852) |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | methylation-sensitive TaqMan QPCR |
| Clinical | No |
| Remarks | For Analysis, Serum PSA, plus Digital rectal Exam plus a marker was chosen for analysis and compared to whether they improved performance over analysis done by only Serum PSA + DRE |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | RASSF1 |